CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail order pharmacy, clinical, disease management, and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, CMS, plans offered on public health insurance, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, LTC pharmacies and on-site pharmacies, retail specialty pharmacy stores, compounding pharmacies and branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was incorporated in 1996 and is headquartered in Woonsocket, Rhode Island.

CVS Health выглядит как крупный, но не безрисковый бизнес: выручка и прибыль остаются огромными, однако рентабельность и ликвидность заметно слабее, чем хотелось бы для устойчивой премии в оценке. P/S 0.25 и P/B 1.32 выглядят недорого, а P/FCF 13.01 тоже не выглядит перегретым, что поддерживает идею умеренной недооценки по активам и денежному потоку. При этом P/E 56.13 существенно выше медианы отрасли, и это настораживает, потому что текущая прибыльность не выглядит достаточно сильной, чтобы оправдать такой мультипликатор без дальнейшего улучшения. Динамика P/E по годам была очень волатильной, что обычно указывает на нестабильность базы прибыли и повышает осторожность в оценке. Маржа валовой прибыли держится около 45% и выглядит относительно стабильной, но операционная маржа и чистая маржа остаются очень слабыми и заметно ниже отраслевых ориентиров. ROE, ROA и ROI также находятся существенно ниже медианы, а их недавние значения хуже, чем в более ранние периоды, что говорит о слабой эффективности капитала. Долговая нагрузка по debt/equity выше отраслевой медианы, а current ratio и quick ratio ниже 1, поэтому баланс нельзя назвать комфортным с точки зрения краткосрочной ликвидности. Долгосрочный долг остаётся высоким, хотя собственный капитал и чистая стоимость компании достаточно велики, чтобы частично смягчать этот риск. Выручка растёт, валовая прибыль увеличивается, а чистая прибыль за TTM положительная и заметная по абсолютной величине, что не позволяет делать слишком пессимистичный вывод. Однако EBITDA и операционная прибыль выглядят слабее, чем хотелось бы при таком масштабе бизнеса, и это ограничивает потенциал переоценки. Дивидендная доходность снизилась по сравнению с предыдущими периодами, поэтому дивидендный фактор сейчас не добавляет сильного аргумента в пользу повышения оценки. В сумме фундаментал скорее поддерживает осторожно-негативную корректировку: бизнес большой и недорогой по выручке и балансу, но качество прибыли, ликвидность и эффективность капитала пока недостаточны для более уверенного апсайда.

CVS Health Corporation

Сильный индекс, незначительно упал. Быки в растерянности.

Strong index, slightly down. The bulls are confused.

Сильный индекс, без изменений. Рынок на стороне быков.

Strong index, flat. The market is on the bulls' side.

Средний индекс, незначительно упал. Приток средств в лонги снизился, но остается положительным.

Medium index, slightly down. The inflow of funds into longs has decreased, but remains positive.

Крупный и недорогой по выручке бизнес с сильной базой активов, но слабой ликвидностью, низкой рентабельностью и повышенным долговым риском.

Molina Healthcare, Inc. MOH received a significant boost after the Illinois Department of Healthcare and Family Services announced its intent to award a HealthChoice Illinois Medicaid Managed Care contract to the company's state subsidiary. The contract is scheduled to begin on Jan. 1, 2027, with an initial term of approximately 4.5 years and extension options of up to an additional 5.5 years, ensuring Molina's continued participation in one of the nation's largest Medicaid markets.
The award secures Molina's place among six health plans selected to participate in Illinois' Medicaid managed care program, serving roughly 3.1 million beneficiaries. As one of the largest Medicaid markets in the country, Illinois represents an important growth and retention opportunity for managed care organizations. Maintaining a presence in the state helps Molina protect a key source of membership and revenues within its largest business segment.
The development comes as Molina continues to navigate industrywide Medicaid enrollment challenges. The company ended the first quarter of 2026 with approximately 4.6 million Medicaid members. By retaining access to Illinois' Medicaid program, Molina reduces the risk of member attrition in a major market while preserving opportunities for future enrollment growth. The award also highlights MOH’s strong competitive position in Medicaid managed care.
While the contract is unlikely to affect near-term earnings since it will not take effect until 2027, it supports Molina's long-term business stability. Coupled with the company's solid 92.0% Medicaid medical care ratio in the first quarter of 2026, the award underscores the resilience of its core Medicaid business and reinforces confidence in its long-term growth prospects.
MOH’s Price Performance
Molina’s shares have gained 11.4% year to date compared with 23.5% growth of the industry.
Image Source: Zacks Investment Research
Zacks Rank & Other Stocks to Consider
Molina currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader Medical space are Centene Corporation CNC, sporting a Zacks Rank #1 (Strong Buy) at present, and Pediatrix Medical Group, Inc. MD and CVS Health Corporation CVS, each carrying a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Centene’s 2026 earnings is pegged at $3.47 per share, indicating 66.8% year-over-year growth. It has witnessed nine upward revisions in the past 60 days, with no movement in the opposite direction. CNC beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 74.9%.
The Zacks Consensus Estimate for Pediatrix Medical’s 2026 bottom line suggests 9.3% year-over-year growth. MD has witnessed four upward estimate revisions over the past 60 days against no movement in the opposite direction. It beat earnings estimates in three of the last four quarters and missed once, delivering an average surprise of 21.3%.
The Zacks Consensus Estimate for CVS Health’s 2026 bottom line suggests 10.2% year-over-year growth. CVS has witnessed 12 upward estimate revisions over the past 60 days against no movement in the opposite direction. It beat earnings estimates in each of the last four quarters, delivering an average surprise of 16.8%.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

MOH Wins Illinois Medicaid Contract, Reinforcing Long-Term Stability

Danaher Corporation DHR has completed the acquisition of Masimo Corp. for $180 per share in cash. The transaction was valued at approximately $9.9 billion in total, including assumed debt and net of acquired cash.
Based in Irvine, CA, Masimo is engaged in developing and producing a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. The company introduced Masimo SET Measure-through Motion and Low Perfusion pulse oximetry in 1995.
Acquisition Rationale of DHR
The latest buyout is in sync with Danaher’s policy of acquiring businesses to strengthen its business and expand market share. The integration of Masimo’s advanced sensor technologies, pulse oximetry solutions and AI-enabled patient-monitoring capabilities is expected to enhance the company’s diagnostics offerings. This acquisition will also enable DHR to provide more comprehensive solutions for acute-care settings, improving clinical decision-making and patient outcomes.
Masimo will operate as a standalone company within the Diagnostics segment, alongside Radiometer, Leica Biosystems, Cepheid and Beckman Coulter Diagnostics.
Masimo Impact Limited in Q2
Danaher maintained its previously issued second-quarter and full-year 2026 guidance, excluding any contribution from Masimo. The company does not expect Masimo to have a material impact on its second-quarter 2026 results. However, DHR plans to update its full-year guidance when it reports second-quarter earnings to reflect the acquisition's expected contribution.
DHR’s Zacks Rank & Price Performance
Danaher is benefiting from strong demand in its bioprocessing business, fueled by rising demand for consumables from pharmaceutical customers. Strength in the filtration business, driven by increased demand for products in the microelectronic end market, also bodes well.
In the past month, this Zacks Rank #3 (Hold) company’s shares gained 8.9% compared with the industry’s 3.6% growth.
Image Source: Zacks Investment Research
However, the company is plagued by weakness in the Diagnostics segment. An increase in the cost of sales may affect the margin performance.
Stocks to Consider
Some better-ranked companies from the same space are discussed below:
Alignment Healthcare, Inc. ALHC currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
ALHC delivered a trailing four-quarter average earnings surprise of 198.8%. In the past 30 days, the Zacks Consensus Estimate for Alignment Healthcare’s 2026 earnings has remained steady.
BrightSpring Health Services, Inc. BTSG currently sports a Zacks Rank of 1. BTSG delivered a trailing four-quarter average earnings surprise of 14.6%.
In the past 30 days, the Zacks Consensus Estimate for BrightSpring’s 2026 earnings has remained steady.
CVS Health Corporation CVS currently carries a Zacks Rank #2 (Buy). CVS delivered a trailing four-quarter average earnings surprise of 16.8%.
In the past 30 days, the Zacks Consensus Estimate for CVS Health’s 2026 earnings has increased 1.1%.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Danaher Boosts Product Portfolio With the Acquisition of Masimo

When assessing a company’s valuation, investors typically rely on metrics such as the price-to-earnings (P/E) ratio and the price-to-sales (P/S) ratio. The P/E ratio measures how much investors are willing to pay for each dollar of a company’s earnings, while the P/S ratio indicates the value the market assigns to each dollar of revenues generated by the business.
Although P/E and P/S multiples are among the most widely used valuation tools, the price-to-book (P/B) ratio is another useful metric, particularly for identifying potentially undervalued stocks and companies with attractive long-term growth prospects. The P/B ratio compares a company’s market value with its book value, providing insight into how the market values the firm's net assets.
The P/B ratio is calculated as:
P/B Ratio = Market Capitalization ÷ Book Value of Equity
or equivalently,
P/B Ratio = Share Price ÷ Book Value per Share.
This metric can help identify attractively priced stocks with upside potential. Some such stocks are StoneCo STNE, USANA Health Sciences USNA, Strategic Education STRA, Nexa Resources NEXA and CVS Health Corporation CVS. Let us understand the concept of book value.
What is Book Value?
There are several ways in which book value can be defined. Book value is the total value that would be left over, according to the company’s balance sheet, if it went bankrupt immediately. In other words, this is what shareholders would theoretically receive if a company liquidates all its assets after paying off all its liabilities.
It is calculated by subtracting total liabilities from the total assets of a company. In most cases, this equates to common stockholders’ equity on the balance sheet. However, depending on the company’s balance sheet, intangible assets should also be subtracted from total assets to determine book value.
Book Value Per Share = (Total Assets – Total Liabilities) ÷ Number of Outstanding Shares
Understanding P/B Ratio
By comparing the book value of equity to its market price, we get an idea of whether a company is under- or overpriced. Like P/E or P/S ratios, it is always better to compare the P/B ratio within industries.
A P/B ratio of less than one means that the stock is trading at less than its book value or the stock is undervalued and, therefore, a good buy. Conversely, a stock with a ratio greater than one can be interpreted as being overvalued or relatively expensive.
For example, a stock with a P/B ratio of 2 means that we pay $2 for every $1 of book value. Thus, the higher the P/B, the more expensive the stock.
But there is a warning. A P/B ratio of less than one can also mean that the company is earning weak or even negative returns on its assets or that the assets are overstated. In such a case, the stock should be shunned because it may be destroying shareholder value. Conversely, the stock’s price may be significantly high — thereby pushing the P/B ratio to more than one — in the likely case that it has become a takeover target, a good enough reason to own the stock.
Moreover, the P/B ratio is not without limitations. It is useful for businesses like finance, investments, insurance and banking or manufacturing companies with many liquid/tangible assets on the books. However, it can be misleading for firms with significant R&D expenditure, high debt, service companies, or those with negative earnings.
In any case, the ratio is not particularly relevant as a standalone number. One should analyze other ratios like P/E, P/S and debt to equity before arriving at a reasonable investment decision.
Screening Parameters
Price to Book (common Equity) less than X-Industry Median: A lower P/B compared with the industry average implies that there is enough room for the stock to gain.
Price to Sales less than X-Industry Median: The P/S ratio determines how much the market values every dollar of the company’s sales/revenues — a lower ratio than the industry makes the stock attractive.
Price to Earnings using F(1) estimate less than X-Industry Median: The P/E ratio (F1) values a company based on its current share price relative to its estimated earnings per share — a lower ratio than the industry is considered better.
PEG less than 1: PEG links the P/E ratio to the future growth rate of the company. The PEG ratio portrays a more complete picture than the P/E ratio. A value of less than 1 indicates that the stock is undervalued, and investors need to pay less for a stock that has bright earnings growth prospects.
Current Price greater than or equal to $5: They must all be trading at a minimum of $5 or higher.
Average 20-Day Volume greater than or equal to 100,000: A substantial trading volume ensures that the stock is easily tradable.
Zacks Rank less than or equal to #2: Zacks Rank #1 (Strong Buy) or 2 (Buy) stocks are known to outperform irrespective of the market environment.
Value Score equal to A or B: Our research shows that stocks with a Value Score of A or B, when combined with a Zacks Rank #1 or 2, offer the best opportunities in the value investing space.
5 Low Price-to-Book Stocks
Here are five of the 14 stocks that qualified for the screening:
StoneCo provides financial technology solutions. The company offers an end-to-end cloud-based technology platform to conduct electronic commerce across in-store, online and mobile channels. StoneCo is based in Sao Paulo, Brazil.
STNE has a Zacks Rank #2 and a Value Score of A. STNE has a projected 3-5-year EPS growth rate of 23.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.
USANA Health Sciences develops and manufactures high-quality nutritional, personal care and weight management products. USANA Health Sciences currently has a Zacks Rank #2 and a Value Score of A. USNA has a projected 3-5-year EPS growth rate of 12.0%.
Herndon, VA-based Strategic Education, through its subsidiaries Strayer University and New York Code and Design Academy (NYCDA), provides a range of post-secondary education and other academic programs in the United States. NYCDA is a New York City-based provider of web and application software development courses. Strategic Education has a projected 3-5-year EPS growth rate of 15%.
STRA currently has a Zacks Rank #2 and a Value Score of A.
Luxembourg City, Brazil-based Nexa Resources is an integrated zinc producer. It is engaged in developing and operating mining and smelting assets, primarily in Latin America. NEXA currently has a Value Score of A and a Zacks Rank #1. NEXA has a projected 3-5-year EPS growth rate of 15.7%.
Headquartered in Woonsocket, RI, CVS Health Corporation (formerly known as CVS Caremark Corporation) is a health solutions company with integrated offerings across the entire spectrum of pharmacy care.
CVS Health has a Zacks Rank #2 and a Value Score of A. CVS has a projected 3-5-year EPS growth rate of 13.7%.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

5 Low Price-to-Book Stocks That Are Worth Buying in June

Danaher Corporation DHR is gaining from strength in its Biotechnology segment. The segment’s core revenues grew 7% on a year-over-year basis in the first quarter of 2026, supported by continued momentum in the bioprocessing business. On a geographical basis, the increase in core sales was driven by higher sales in Western Europe and China.
The bioprocessing business’ performance is supported by an increase in demand for consumables from large pharmaceutical customers. Also, solid demand from pharmaceutical customers for monoclonal antibodies (mAbs) has been buoying the bioprocessing business. In the first quarter of 2026, orders for bioprocessing equipment increased more than 30%. For 2026, Danaher expects core revenues from the bioprocessing business to increase in high single-digits on a year-over-year basis. Also, solid momentum in the medical filtration and research consumables business bodes well for the Biotechnology segment.
However, the Biotechnology segment is facing challenges owing to lower demand for medical filtration and research consumables in the discovery and medical business. Declining demand for equipment is also acting as a headwind for it.
Despite these challenges, Danaher anticipates core revenues from the Biotechnology segment to increase in mid-single digits on a year-over-year basis in the second quarter of 2026. An increase in demand for products within the bioprocessing business is expected to support stable segment performance in the coming quarters.
Segment Snapshot of DHR's Peers
Among its major peers, Labcorp Holdings Inc.’s LH Biopharma Laboratory Services segment generated net sales of $780.6 million in the first quarter of 2026, up 8.2% year over year. This was driven by Labcorp’s strong drug development capabilities and scientific expertise. Labcorp derived 22.1% of its total revenues from this segment during the quarter.
Its another peer, CVS Health Corporation’s CVS Health Services segment reported net sales of $48.24 billion in the first quarter of 2026, up 11% year over year. CVS Health generated 48% of its total sales from this segment in the quarter. Favorable pharmacy drug mix and brand inflation aided the segment’s results in the second quarter.
DHR's Price Performance, Valuation and Estimates
Shares of Danaher have gained 10.5% in the past month compared with the industry’s growth of 3.1%.
Image Source: Zacks Investment Research
From a valuation standpoint, DHR is trading at a forward price-to-earnings ratio of 21.03X, above the industry’s average of 15.04X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for DHR’s 2026 earnings has increased over the past 60 days.
Image Source: Zacks Investment Research
The company currently carries a Zacks Rank #3 (Hold).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.7% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Strong Performance Continues at DHR's Biotechnology Unit: What's Next?

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. CVS Health (CVS) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
CVS Health is one of 888 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. CVS Health is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for CVS' full-year earnings has moved 4% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that CVS has returned about 20.9% since the start of the calendar year. In comparison, Medical companies have returned an average of -4.4%. This means that CVS Health is performing better than its sector in terms of year-to-date returns.
Align Technology (ALGN) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 7.4%.
For Align Technology, the consensus EPS estimate for the current year has increased 3.9% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, CVS Health belongs to the Medical Services industry, a group that includes 62 individual stocks and currently sits at #109 in the Zacks Industry Rank. On average, stocks in this group have lost 8.1% this year, meaning that CVS is performing better in terms of year-to-date returns.
Align Technology, however, belongs to the Medical - Dental Supplies industry. Currently, this 13-stock industry is ranked #64. The industry has moved -6.4% so far this year.
CVS Health and Align Technology could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Has CVS Health (CVS) Outpaced Other Medical Stocks This Year?

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $180.8 million dollar outflow -- that's a 0.2% decrease week over week (from 317,400,000 to 316,650,000). Among the largest underlying components of IWD, in trading today CVS Health Corporation (Symbol: CVS) is up about 1.2%, Chubb Ltd (Symbol: CB) is up about 2.9%, and Dell Technologies Inc (Symbol: DELL) is lower by about 4.3%. For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average:
Looking at the chart above, IWD's low point in its 52 week range is $188.55 per share, with $241.35 as the 52 week high point — that compares with a last trade of $239.16. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Further IWD Research:
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

IWD, CVS, CB, DELL: Large Outflows Detected at ETF

Key Points
CVS Caremark will cover Eli Lilly's weight loss medicines.
This decision could help boost the drugmaker's sales.
Eli Lilly's prospects remain attractive even at current levels.
Despite Eli Lilly's (NYSE: LLY) dominance in the weight management market, the company has encountered several obstacles in this field, including spotty insurance coverage for its anti-obesity medicine, Zepbound. If Eli Lilly could make headway in that area, it could boost the already fast-growing sales of this medicine. That's why recent news from CVS Health (NYSE: CVS) was so important. Let's look deeper into it.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
CVS Health does a 180
On May 28, CVS Caremark, the pharmacy benefits manager (PBM) under CVS Health's umbrella, announced it would start covering Zepbound on Oct. 1. This news is especially important, as CVS had previously removed the medicine from its formulary. So, this is quite the reversal. Further, CVS Health will also cover Eli Lilly's new GLP-1 pill, Foundayo, effective June 1.
These developments allowed Eli Lilly to catch up to its biggest competitor, Novo Nordisk, whose competing subcutaneous and oral weight loss medicines were already covered by CVS Caremark. Also, as Eli Lilly noted, this decision means the three largest PBMs in the U.S. will cover Zepbound and Foundayo. CVS's decision will help more patients access these medicines at reasonable prices. The expanded access may also help Eli Lilly fend off the threat posed by some telemedicine companies that have built a business model around offering cheaper, knockoff versions of Zepbound.
Is Eli Lilly stock a buy?
Can Eli Lilly continue riding the weight loss tailwind over the next few years, even as competition intensifies? Yes, it can. The drugmaker's coverage progress and early success with Foundayo -- which was only approved in April -- highlight that the anti-obesity market is far from having peaked. Some 80% of Foundayo's patients had never taken GLP-1s before, perhaps because they didn't like injections.
Eli Lilly's broad portfolio can help address the needs of many others who are still sitting on the sidelines. Meanwhile, the company's revenue and earnings are growing much faster than those of its similarly sized peers and continue to impress Wall Street. In the first quarter, Eli Lilly's sales jumped by 56% year over year to $19.8 billion, while its adjusted net earnings per share soared to $8.55, up 156% from the year-ago period.
Further, Eli Lilly has a meaningful lineup and pipeline beyond its core diabetes and weight loss products. Over the next five years, the company should ramp up sales of non-GLP-1 drugs while launching several new ones. Some might argue that, although Eli Lilly is performing well, its shares are far too expensive. They are trading at 29.3x forward earnings, versus an average of 16.9x for healthcare stocks. But Eli Lilly has earned a premium given its fantastic results and strong pipeline. That's why the stock remains attractive at current levels.
Should you buy stock in Eli Lilly right now?
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $439,632!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,316,532!*
Now, it’s worth noting Stock Advisor’s total average return is 959% — a market-crushing outperformance compared to 210% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of June 5, 2026.
Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool has positions in and recommends Eli Lilly. The Motley Fool recommends CVS Health and Novo Nordisk. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

CVS Health Just Announced Fantastic News to Eli Lilly Stock Investors

The S&P 500 Index ($SPX) (SPY) on Thursday closed up +0.41%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +1.73%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.53%. June E-mini S&P futures (ESM26) rose +0.36%, and June E-mini Nasdaq futures (NQM26) fell -0.47%.
Stock indexes settled mixed on Thursday, with the Dow Jones industrials posting a new all-time high. The overall market shook off early weakness on Thursday and pushed higher as a -3% plunge in crude oil prices knocked T-note yields lower, with the 10-year T-note yield falling -2 bp to 4.47%. Also, the rally in bank stocks and managed healthcare companies lifted the broader market, pushing the Dow Jones Industrial Average to a new record high.
Join 200K+ Subscribers: Find out why the midday Barchart Brief newsletter is a must-read for thousands daily.
The weakness in technology stocks on Thursday weighed on the broader market, keeping the Nasdaq 100 in negative territory. Broadcom fell more than -12% to lead chipmakers lower after its forecast for artificial-intelligence revenue in the current quarter fell short of expectations. Also, CrowdStrike Holdings closed down more than -3% to lead cybersecurity stocks lower, despite reporting better-than-expected Q1 earnings, as the report wasn’t strong enough to lift the stock, which has more than doubled from a March low.
Weaker crude oil prices are a positive factor for stocks and bonds, as WTI crude oil fell more than -3% on Thursday after the US late Wednesday said Israel and Lebanon agreed to a ceasefire if Hezbollah also stops fighting and withdraws militants from areas near the border with Israel. Iran insists a peace deal with the US requires a ceasefire in Lebanon. The agreement would require the Lebanese army to take over after the withdrawal of Israeli troops. However, Hezbollah militants said they refused to abide by the conditions of the ceasefire announced by the US State Department, and clashes continued in southern Lebanon. Iranian Foreign Minister Abbas Araghchi said that “Communications between Iran and the US have not been cut off, but no tangible progress has been achieved in the negotiating process.”
Thursday’s US economic news was mixed for stocks after weekly jobless claims rose more than expected to a 3.75-month high and Q1 nonfarm productivity was revised lower. Conversely, Q1 unit labor costs were unexpectedly revised lower, easing concerns over wage pressures.
US weekly initial unemployment claims rose +13,000 to a 3.75-month high of 225,000, showing a weaker labor market than expectations of 215,000.
US Q1 nonfarm productivity was revised downward to 0.3% from the previously reported 0.8%, weaker than expectations of 0.4%. Q1 unit labor costs were unexpectedly revised downward to 1.8% from 2.3%, weaker than expectations of an upward revision to 2.4%.
The markets are discounting a 2% chance of a +25 bp rate hike at the next FOMC meeting on June 16-17.
The generally favorable Q1 earnings season is winding down. As of Thursday, 83% of the 494 S&P 500 companies that reported Q1 earnings have beaten estimates. Q1 S&P 500 earnings are projected to climb +12% y/y, according to Bloomberg Intelligence. Stripping out the technology sector, Q1 earnings are projected to increase around +3%, the weakest in two years.
Overseas stock markets settled mixed on Thursday. The Euro Stoxx 50 closed up +0.82%. China's Shanghai Composite closed down -0.64%. Japan's Nikkei Stock Average closed down -1.36%.
Interest Rates
September 10-year T-notes (ZNU6) on Thursday closed up +4.5 ticks, and the 10-year T-note yield fell -2.4 bp to 4.471%. T-note prices moved higher on Thursday, supported by a -3% decline in WTI crude oil prices, which has lowered inflation expectations. The 10-year breakeven inflation rate fell to a 6-week low of 2.365% on Thursday. Fed-friendly US economic news was also positive for T-notes, following weekly jobless claims that rose more than expected and Q1 unit labor costs that were unexpectedly revised lower. T-notes fell back from their best level as stocks rebounded, dampening safe-haven demand for government debt securities.
European government bond yields moved lower on Thursday. The 10-year German Bund yield fell from a 1.5-week high of 3.043% and finished down -1.3 bp to 3.023%. The 10-year UK gilt yield fell -3.3 bp to 4.898%.
Eurozone Apr retail sales fell -0.4% m/m, weaker than expectations of -0.3% m/m.
Swaps are discounting a 98% chance of a +25 bp ECB rate hike at its next policy meeting on June 11.
US Stock Movers
Humana (HUM) closed up more than +6% to lead managed healthcare stocks higher and gainers in the S&P 500 after Morgan Stanley raised its price target on the stock to $240 from $217. Also, Centene (CNC) closed up more than +5%, and UnitedHealth Group (UNH) closed up more than +5% to lead gainers in the Dow Jones Industrials after Bank of America Global Research upgraded the stock to buy from neutral with a price target of $450. In addition, Elevance Health (ELV) and Molina Healthcare(MOH) closed up more than +4%, and Cigna Group (CI) and CVS Health (CVS) closed up more than +3%. Finally, Cardinal Health (CAH) closed up more than +2%.
Asset managers and bank stocks rallied on Thursday, lifting the broader market. Blackstone (BX) closed up more than +7% to lead gainers in the S&P 500, and Franklin Resources (BEN) closed up more than +5%. Also, Goldman Sachs (GS), Fifth Third Bank (FITB), and US Bancorp (USB) closed up more than +4%. In addition, JPMorgan Chase (JPM), Morgan Stanley (MS), Citigroup (C), Wells Fargo (WFC), Citizens Financial Group (CFG), M&T Bank (MTB), and BlackRock (BLK) closed up more than +3%.
Chipmakers and AI-infrastructure stocks retreated on Thursday, led by a -12% plunge in Broadcom (AVGO), the largest decliner in the Nasdaq 100, after giving an outlook that was seen as underwhelming, given the industry’s AI-related demand. Also, Micron Technology (MU) closed down more than -7%, and ARM Holdings Plc (ARM) closed down more than -4%. In addition, Advanced Micro Devices (AMD), Qualcomm (QCOM), Sandisk (SNDK), and Western Digital (WDC) closed down more than -3%, and Lam Research (LRCX) and Analog Devices (ADI) closed down more than -2%.
Medtronic Plc (MDT) closed up more than +5% after BTIG LLC upgraded the stock to buy from neutral with a price target of $90.
RTX Corp (RTX) closed up +4% after Jeffries upgraded the stock to buy from hold with a price target of $220.
Alnylam Pharmaceuticals (ALNY) closed up more than +3% to lead gainers in the Nasdaq 100 after entering into a strategic AI collaboration with Inceptive Nucleics valued at up to $2 billion to accelerate the discovery and design of RNAi therapeutics.
Brown-Forman (BF.B) closed up more than +2% after reporting Q4 gross margin of 62.6%, stronger than the consensus of 57.5%.
Zoetis (ZTS) closed up more than +2% after KeyBanc Capital Markets said the cattle screwworm parasite could be a potential catalyst for the company’s livestock portfolios, as it has approved medications to prevent and treat the parasite in livestock.
PVH Corp (PVH) closed down more than -20% after forecasting 2027 adjusted EPS of $11.80 to $12.10, weaker than the consensus of $12.24.
Ciena Corp (CIEN) closed down more than -13% to lead losers in the S&P 500 despite reporting better-than-expected Q2 earnings, as Bloomberg Intelligence said the company’s full-year sales outlook may be viewed as underwhelming amid heightened expectations.
Five Below (FIVE) closed down more than -13% despite reporting stronger-than-expected Q1 earnings results, as Jeffries said the company’s growth rate might be peaking.
CrowdStrike Holdings (CRWD) closed down more than -3% after its Q1 earnings beat wasn’t strong enough to lift the stock, which has more than doubled from a March low.
AT&T (T) closed down more than -3% and Verizon Communications (VZ) closed down more than -3% to lead losers in the Dow Jones Industrials after the US Supreme Court ruled that telecommunications companies can’t immediately demand a jury trial when hit with a Federal Communications Commission fine.
Earnings Reports(6/5/2026)
ABM Industries Inc (ABM), G-III Apparel Group Ltd (GIII), Lifezone Metals Ltd (LZM).
On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Stocks Rebound on Strength in Banks and Managed Healthcare

The S&P 500 Index ($SPX) (SPY) today is up +0.02%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +1.49%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.90%. June E-mini S&P futures (ESM26) are up +0.02%, and June E-mini Nasdaq futures (NQM26) are down -0.86%.
Stock indexes are mixed today, with the Dow Jones industrials posting a new all-time high. The broader market is under pressure today amid weakness in technology stocks. Broadcom is down more than -14% to lead chipmakers lower after its forecast for artificial-intelligence revenue in the current quarter fell short of expectations. Also, CrowdStrike Holdings is down more than -8% to lead cybersecurity stocks lower, despite reporting better-than-expected Q1 earnings, as the report wasn’t strong enough to lift the stock, which has more than doubled from a March low. However, the strength in managed healthcare stocks today is limiting overall market losses and helping push the Dow Jones Industrial Average to a new record high.
Join 200K+ Subscribers: Find out why the midday Barchart Brief newsletter is a must-read for thousands daily.
Weaker crude oil prices are a positive factor for stocks and bonds, with WTI crude oil down more than -3% today after the US late Wednesday said Israel and Lebanon agreed to a ceasefire if Hezbollah also stops fighting and withdraws militants from areas near the border with Israel. The agreement would require the Lebanese army to take over after the withdrawal of Israeli troops. Iran insists a deal with the US requires a ceasefire in Lebanon. Iranian Foreign Minister Abbas Araghchi said that “Communications between Iran and the US have not been cut off, but no tangible progress has been achieved in the negotiating process.”
Today’s US economic news was mixed for stocks after weekly jobless claims rose more than expected to a 3.75-month high and Q1 nonfarm productivity was revised lower. Conversely, Q1 unit labor costs were unexpectedly revised lower, easing concerns over wage pressures.
US weekly initial unemployment claims rose +13,000 to a 3.75-month high of 225,000, showing a weaker labor market than expectations of 215,000.
US Q1 nonfarm productivity was revised downward to 0.3% from the previously reported 0.8%, weaker than expectations of 0.4%. Q1 unit labor costs were unexpectedly revised downward to 1.8% from 2.3%, weaker than expectations of an upward revision to 2.4%.
The markets are discounting a 2% chance of a +25 bp rate hike at the next FOMC meeting on June 16-17.
The generally favorable Q1 earnings season is winding down. As of today, 84% of the 485 S&P 500 companies that reported Q1 earnings have beaten estimates. Q1 S&P 500 earnings are projected to climb +12% y/y, according to Bloomberg Intelligence. Stripping out the technology sector, Q1 earnings are projected to increase around +3%, the weakest in two years.
Overseas stock markets are mixed today. The Euro Stoxx 50 is up +0.51%. China's Shanghai Composite closed down -0.64%. Japan's Nikkei Stock Average closed down -1.36%.
Interest Rates
September 10-year T-notes (ZNU6) today are up +8 ticks, and the 10-year T-note yield is down -3.6 bp to 4.459%. T-note prices are moving higher today, supported by a -2% decline in WTI crude oil prices, which has lowered inflation expectations. The 10-year breakeven inflation rate fell to a 6-week low of 2.366% today. Fed-friendly US economic news was also positive for T-notes, following weekly jobless claims that rose more than expected and Q1 unit labor costs that were unexpectedly revised lower.
European government bond yields are moving lower today. The 10-year German Bund yield fell from a 1.5-week high of 3.043% and is down -1.5 bp to 3.021%. The 10-year UK gilt yield is down -2.7 bp to 4.904%.
Eurozone Apr retail sales fell -0.4% m/m, weaker than expectations of -0.3% m/m.
Swaps are discounting a 98% chance of a +25 bp ECB rate hike at its next policy meeting on June 11.
US Stock Movers
Chipmakers and AI-infrastructure stocks are slumping today, led by a -14% plunge in Broadcom (AVGO), the largest decliner in the Nasdaq 100, after giving an outlook that was seen as underwhelming, given the industry’s AI-related demand. Also, Micron Technology (MU) is down more than -8%, and ARM Holdings Plc (ARM) is down more than -5%. In addition, Advanced Micro Devices (AMD), Qualcomm (QCOM), Sandisk (SNDK), and Lam Research (LRCX) are down more than -3%. Finally, Western Digital (WDC), Seagate Technology Holdings Plc (STX), Analog Devices (ADI), KLA Corp (KLAC), and Intel (INTC) are down more than -2%.
Cryptocurrency-exposed stocks are falling today, with Bitcoin (^BTCUSD) down more than -1% at a 3.75-month low. Galaxy Digital Holdings (GLXY) is down more than -5%, MARA Holdings (MARA) is down more than -4%, and Riot Platforms (RIOT) is down more than -3%. Also, Coinbase Global (COIN) is down -0.28%.
Humana (HUM) is up more than +7% to lead managed healthcare stocks higher and gainers in the S&P 500 after Morgan Stanley raised its price target on the stock to $240 from $217. Also, Centene (CNC) is up more than +6%, and UnitedHealth Group (UNH) is up more than +5% to lead gainers in the Dow Jones Industrials after Bank of America Global Research upgraded the stock to buy from neutral with a price target of $450. In addition, Elevance Health (ELV), Cigna Group (CI), and Molina Healthcare(MOH) are up more than +4%, and CVS Health (CVS) and Cardinal Health (CAH) are up more than +2%.
PVH Corp (PVH) is down more than -24% after forecasting 2027 adjusted EPS of $11.80 to $12.10, weaker than the consensus of $12.24.
Ciena Corp (CIEN) is down more than -18% to lead losers in the S&P 500 despite reporting better-than-expected Q2 earnings, as Bloomberg Intelligence said the company’s full-year sales outlook may be viewed as underwhelming amid heightened expectations.
Five Below (FIVE) is down more than -13% despite reporting stronger-than-expected Q1 earnings results, as Jeffries said the company’s growth rate might be peaking.
CrowdStrike Holdings (CRWD) is down more than -7% after its Q1 earnings beat wasn’t strong enough to lift the stock, which has more than doubled from a March low.
Alnylam Pharmaceuticals (ALNY) is up more than +5% to lead gainers in the Nasdaq 100 after entering into a strategic AI collaboration with Inceptive Nucleics valued at up to $2 billion to accelerate the discovery and design of RNAi therapeutics.
Medtronic Plc (MDT) is up more than +4% after BTIG LLC upgraded the stock to buy from neutral with a price target of $90.
Zoetis (ZTS) is up more than +4% after KeyBanc Capital Markets said the cattle screwworm parasite could be a potential catalyst for the company’s livestock portfolios, as it has approved medications to prevent and treat the parasite in livestock.
RTX Corp (RTX) is up more than +3% after Jeffries upgraded the stock to buy from hold with a price target of $220.
Brown-Forman (BF.B) is up more than +1% after reporting Q4 gross margin of 62.6%, stronger than the consensus of 57.5%.
Earnings Reports(6/4/2026)
Brown-Forman Corp (BF/B), Ciena Corp (CIEN), Cooper Cos Inc/The (COO), Docusign Inc (DOCU), Guidewire Software Inc (GWRE), Lululemon Athletica Inc (LULU), Rubrik Inc (RBRK), Samsara Inc (IOT), Toro Co/The (TTC).
On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Stocks Mixed as Tech Weakness Weighs

The S&P 500 Index ($SPX) (SPY) today is down -0.16%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +1.41%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -1.23%. June E-mini S&P futures (ESM26) are down -0.14%, and June E-mini Nasdaq futures (NQM26) are down -1.16%.
Stock indexes are mixed today, with the Dow Jones industrials posting a new all-time high. The broader market is under pressure today amid weakness in technology stocks. Broadcom is down more than -15% to lead chipmakers lower after its forecast for artificial-intelligence revenue in the current quarter fell short of expectations. Also, CrowdStrike Holdings is down more than 6% to lead cybersecurity stocks lower, despite reporting better-than-expected Q1 earnings, as the report wasn’t strong enough to lift the stock, which has more than doubled from a March low. Strength in managed healthcare stocks today is helping push the Dow Jones Industrial Average to a record high.
Join 200K+ Subscribers: Find out why the midday Barchart Brief newsletter is a must-read for thousands daily.
Weaker crude oil prices are a positive factor for stocks and bonds, with WTI crude oil down more than -3% today after the US late Wednesday said Israel and Lebanon agreed to a ceasefire if Hezbollah also stops fighting and withdraws militants from areas near the border with Israel. The agreement would require the Lebanese army to take over after the withdrawal of Israeli troops. Iran insists a deal with the US requires a ceasefire in Lebanon. Iranian Foreign Minister Abbas Araghchi said that “Communications between Iran and the US have not been cut off, but no tangible progress has been achieved in the negotiating process.”
Today’s US economic news was mixed for stocks after weekly jobless claims rose more than expected to a 3.75-month high and Q1 nonfarm productivity was revised lower. Conversely, Q1 unit labor costs were unexpectedly revised lower, easing concerns over wage pressures.
US weekly initial unemployment claims rose +13,000 to a 3.75-month high of 225,000, showing a weaker labor market than expectations of 215,000.
US Q1 nonfarm productivity was revised downward to 0.3% from the previously reported 0.8%, weaker than expectations of 0.4%. Q1 unit labor costs were unexpectedly revised downward to 1.8% from 2.3%, weaker than expectations of an upward revision to 2.4%.
The markets are discounting a 2% chance of a +25 bp rate hike at the next FOMC meeting on June 16-17.
The generally favorable Q1 earnings season is winding down. As of today, 84% of the 485 S&P 500 companies that reported Q1 earnings have beaten estimates. Q1 S&P 500 earnings are projected to climb +12% y/y, according to Bloomberg Intelligence. Stripping out the technology sector, Q1 earnings are projected to increase around +3%, the weakest in two years.
Overseas stock markets are mixed today. The Euro Stoxx 50 is up +0.51%. China's Shanghai Composite closed down -0.64%. Japan's Nikkei Stock Average closed down -1.36%.
Interest Rates
September 10-year T-notes (ZNU6) today are up +8 ticks, and the 10-year T-note yield is down -3.6 bp to 4.459%. T-note prices are moving higher today, supported by a -2% decline in WTI crude oil prices, which has lowered inflation expectations. The 10-year breakeven inflation rate fell to a 6-week low of 2.366% today. Fed-friendly US economic news was also positive for T-notes, following weekly jobless claims that rose more than expected and Q1 unit labor costs that were unexpectedly revised lower.
European government bond yields are moving lower today. The 10-year German Bund yield fell from a 1.5-week high of 3.043% and is down -1.5 bp to 3.021%. The 10-year UK gilt yield is down -2.7 bp to 4.904%.
Eurozone Apr retail sales fell -0.4% m/m, weaker than expectations of -0.3% m/m.
Swaps are discounting a 98% chance of a +25 bp ECB rate hike at its next policy meeting on June 11.
US Stock Movers
Chipmakers and AI-infrastructure stocks are slumping today, led by a -15% plunge in Broadcom (AVGO), the largest decliner in the Nasdaq 100, after giving an outlook that was seen as underwhelming, given the industry’s AI-related demand. Also, Micron Technology (MU), ARM Holdings Plc (ARM), and Marvell Technology (MRVL) are down more than -5%, and Applied Materials (AMAT) and Lam Research (LRCX) are down more than -3%. In addition, KLA Corp (KLAC), Intel (INTC), Qualcomm (QCOM), Analog Devices (ADI), and ASML Holding NV (ASML) are down more than -2%.
Cybersecurity stocks are retreating for a second day today, led by an -8% decline in CrowdStrike Holdings (CRWD) after its Q1 earnings beat wasn’t strong enough to lift the stock that has more than doubled from a March low. Also, Palo Alto Networks (PANW) and Cloudflare (NET) are down more than -2%, and Okta (OKTA) is down -0.83%.
Cryptocurrency-exposed stocks are falling today, with Bitcoin (^BTCUSD) down more than -1% at a 3.75-month low. Galaxy Digital Holdings (GLXY) is down more than -4%, and MARA Holdings (MARA) and Riot Platforms (RIOT) are down more than -3%. Also, Coinbase Global (COIN) is down -0.44%.
UnitedHealth Group (UNH) is up more than +6% to health insurance stocks higher and lead gainers in the S&P 500 and Dow Jones Industrials after Bank of America Global Research upgraded the stock to buy from neutral with a price target of $450. Also, Humana (HUM) is up more than +5%, and Centene (CNC) and Elevance Health (ELV) are up more than +4%. In addition, Cigna Group (CI) and CVS Health (CVS) are up more than +3%, and Cardinal Health (CAH) is up more than +2%.
PVH Corp (PVH) is down more than -27% after forecasting 2027 adjusted EPS of $11.80 to $12.10, weaker than the consensus of $12.24.
Ciena Corp (CIEN) is down more than -19% to lead losers in the S&P 500 despite reporting better-than-expected Q2 earnings, as Bloomberg Intelligence said the company’s full-year sales outlook may be viewed as underwhelming amid heightened expectations.
Five Below (FIVE) is down more than -10% despite reporting stronger-than-expected Q1 earnings results, as Jeffries said the company’s growth rate might be peaking.
Brown-Forman (BF.B) is up more than +4% after reporting Q4 gross margin of 62.6%, stronger than the consensus of 57.5%.
Medtronic Plc (MDT) is up more than +4% after BTIG LLC upgraded the stock to buy from neutral with a price target of $90.
RTX Corp (RTX) is up more than +3% after Jeffries upgraded the stock to buy from hold with a price target of $220.
Alnylam Pharmaceuticals (ALNY) is up more than +2% after entering into a strategic AI collaboration with Inceptive Nucleics valued at up to $2 billion to accelerate the discovery and design of RNAi therapeutics.
Earnings Reports(6/4/2026)
Brown-Forman Corp (BF/B), Ciena Corp (CIEN), Cooper Cos Inc/The (COO), Docusign Inc (DOCU), Guidewire Software Inc (GWRE), Lululemon Athletica Inc (LULU), Rubrik Inc (RBRK), Samsara Inc (IOT), Toro Co/The (TTC).
On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

CVS Health Corporation

Options Strategies